Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10768
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFajri, Dessy Wen
dc.contributor.authorBrand, Caroline Aen
dc.contributor.authorDharmage, Shyamali Cen
dc.contributor.authorMartin, Belinda Jen
dc.contributor.authorBuchanan, Russell R Cen
dc.contributor.authorSchachna, Lionelen
dc.date.accessioned2015-05-16T00:19:14Z-
dc.date.available2015-05-16T00:19:14Z-
dc.date.issued2009-02-14en
dc.identifier.citationClinical Rheumatology 2009; 28(5): 599-602en
dc.identifier.govdoc19219481en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10768en
dc.description.abstractTumour necrosis factor inhibitor (TNFi) therapy, either intravenous (IV) or subcutaneous (SQ), demonstrates similar efficacy in ankylosing spondylitis (AS). The objective of this study was to examine factors influencing patient preference of TNFi. Fifty-nine (79.7%) participants were male with mean age 43.9 years and disease duration of 22.0 years. Fifty-nine patients (79.7%) agreed with the statement 'My doctor gave me a choice and I made a decision based on my personal preference'. Patients commenced first on IV TNFi most commonly cited reduced frequency of injections (96.6%), administration by a trained professional (89.7%) and use of infusion time for leisure activities (86.2%). Patients commenced on SQ TNFi cited flexibility with timing of treatment (80%), shortened administration time (73.3%) and the convenience of home therapy (73.3%). Shared clinical decision-making between clinicians and patients may be desirable for AS patients commencing TNFi therapy.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAntirheumatic Agents.therapeutic useen
dc.subject.otherCommunicationen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherInfusions, Intravenousen
dc.subject.otherInjections, Subcutaneousen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPatient Satisfactionen
dc.subject.otherQuestionnairesen
dc.subject.otherSpondylitis, Ankylosing.drug therapyen
dc.subject.otherTreatment Outcomeen
dc.subject.otherTumor Necrosis Factor-alpha.antagonists & inhibitorsen
dc.titleWhat factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical rheumatologyen
dc.identifier.affiliationDepartment of Rheumatology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1007/s10067-009-1104-4en
dc.description.pages599-602en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/19219481en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherBuchanan, Russell R C
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.grantfulltextopen-
crisitem.author.deptRheumatology-
crisitem.author.deptRheumatology-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
19219481.pdf47.98 kBAdobe PDFView/Open
Show simple item record

Page view(s)

20
checked on Mar 1, 2024

Download(s)

56
checked on Mar 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.